跳到正文
openFDA 已分级药品召回执法报告·· 26 天前精选AI 评分73

FDA 执法报告 D-0052-2027 显示 Pfizer 的 Levoxyl 175 mcg 因稳定性试验确认 OOS 含量不合格被列为 II 类召回

FDA drug enforcement D-0052-2027: Pfizer — Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

AI 导读

FDA 药品执法报告 D-0052-2027 将 Pfizer 的 Levoxyl(左甲状腺素钠片,USP)175 mcg 片剂列为 II 类召回,原因为稳定性试验中确认含量不符合标准(OOS)导致效价不足。

推荐理由

记录列出稳定性试验确认含量不合格导致的效价不足召回,含批次、分销范围与状态,可用于核对召回档案。

正文 · AI 翻译

FDA 药品召回执法报告 — D-0052-2027

报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。

范围:一条已分类的药品召回记录;event_id 可能归组多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。

openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。

完整的官方产品记录(包括 openFDA 统一标识符):

{

"address_1": "66 Hudson Blvd",

"address_2": "",

"center_classification_date": "20261016",

"city": "Manhattan",

"classification": "Class II",

"code_info": "Lot # 24W06, Exp: 11/30/2026",

"country": "United States",

"distribution_pattern": "US Nationwide and Puerto Rico",

"event_id": "99963",

"initial_firm_notification": "Letter",

"more_code_info": "",

"openfda": {

"application_number": [

"NDA021301"

],

"brand_name": [

"LEVOXYL"

],

"generic_name": [

"LEVOTHYROXINE SODIUM"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Pfizer Laboratories Div Pfizer Inc"

],

"package_ndc": [

"60793-850-10",

"60793-850-01",

"60793-851-10",

"60793-851-01",

"60793-852-10",

"60793-852-01",

"60793-853-10",

"60793-853-01",

"60793-854-10",

"60793-854-01",

"60793-855-10",

"60793-855-01",

"60793-856-10",

"60793-856-01",

"60793-857-10",

"60793-857-01",

"60793-858-10",

"60793-858-01",

"60793-859-10",

"60793-859-01",

"60793-860-10",

"60793-860-01"

],

"product_ndc": [

"60793-850",

"60793-851",

"60793-852",

"60793-853",

"60793-854",

"60793-855",

"60793-856",

"60793-857",

"60793-858",

"60793-859",

"60793-860"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"ORAL"

],

"rxcui": [

"892246",

"892251",

"966157",

"966164",

"966170",

"966175",

"966184",

"966190",

"966194",

"966200",

"966204",

"966211",

"966220",

"966221",

"966222",

"966224",

"966225",

"966248",

"966249",

"966253",

"966270",

"966283"

],

"spl_id": [

"8ce3c272-807b-4a86-aa58-034013814264"

],

"spl_set_id": [

"758588c3-c63e-491b-0aa2-4f50d80cb174"

],

"substance_name": [

"LEVOTHYROXINE SODIUM"

],

"unii": [

"9J765S329G"

],

"upc": [

"0360793858012",

"0360793855011",

"0360793852010",

"0360793860015",

"0360793850016",

"0360793853017",

"0360793854014",

"0360793857015",

"0360793859019",

"0360793856018",

"0360793851013"

]

},

"postal_code": "10001-2189",

"product_description": "Levoxyl(左甲状腺素钠片,USP),片剂,175 mcg,100 片/瓶,处方药,由 Pfizer Inc. 分销,地址 New York, NY 10017,奥地利制造。NDC 60793-859-01。",

"product_quantity": "15,815 瓶(100 片/瓶)",

"product_type": "Drugs",

"reason_for_recall": "含量不足:稳定性试验中确认含量测定结果不符合标准(OOS)。",

"recall_initiation_date": "20260929",

"recall_number": "D-0052-2027",

"recalling_firm": "Pfizer",

"report_date": "20261028",

"state": "NY",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov